Navigation Links
Valeant Pharmaceuticals Reports Fourth Quarter and Full Year Financial Results
Date:2/24/2009

d amortization expense in the three and twelve months ended December 31, 2008 and December 31, 2007 of $215.7 million and $257.6 million and $23.0 million and $83.7 million, respectively. To supplement the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as acquired in-process research and development, restructuring, asset impairments and dispositions, amortization expense and the tax effect of such charges. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP; therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Note: Currency effect is determined by comparing adjusted 2008 reported amounts, calculated using 2007 monthly average exchange rates, to the actual 2007 reported amounts. Constant currency sales is not a GAAP- defined measure of revenue growth. Constant currency sales as defined and presented by us may not be comparable to similar measures reported by other companies. Valeant Pharmaceuticals International Table 5 Consolidated Balance Sheet and Other Data (In thousands) As of As of December 31, December 31, Balanc
'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
2. Valeant Pharmaceuticals to Announce 2008 Fourth Quarter and Year Results on February 24, 2009
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... Good Shepherd Children’s Home announces 53rd year of caring for ... Christian-based home, the children learn biblical principles and are taught ... their life. , A day in the life… , ... children begin to awake and prepare for the day ahead. ... Sleepily, she crawls out of bed and scrambles to ...
(Date:3/30/2015)... 30, 2015 GoHooper.com announces new website ... providing medical care to infants, children and adolescents and ... children. , The owner/provider Mark Hughes, MD, FAAP ... strive to provide expertise in the extensive range of ... care from health professionals who meet the medical field's ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 Health Fitness Revolution, ... Trainer in the World Samir Becic, has created a new ... 2015 , which recognizes the world’s fittest leaders in terms ... first and only list of its kind to detail the ... ministers. , Among the world leaders profiled on the list ...
(Date:3/30/2015)... Columbus, OH (PRWEB) March 30, 2015 ... in product liability lawsuits, notes that the number of ... federal multidistrict litigation underway in U.S. District Court, District ... established in December 2014. "According to an update released ... on March 16th, at least 493 Syngenta lawsuits are ...
(Date:3/30/2015)... March 30, 2015 The partners of ... the grand opening of the Bella Diosa Laser Med ... the finest in laser med spa treatments. , February ... Spa and the partnership bridges the medical services provided ... treatments provided by Bella Diosa for both women and ...
Breaking Medicine News(10 mins):Health News:Good Shepherd Children’s Home Announces 53rd Year of Providing a Safe-Haven for Children in Need 2Health News:Nashville Web Design Company Announces New Site Launch For Pediatrics Doctor 2Health News:The Top 13 Fittest Heads of State: Why Putin Might Be No. 1 in Health and Fitness 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 3Health News:Yonkers Celebrates the Grand Opening of Bella Diosa 2
... ... set…GO! Summer kicks off each year with the City of Laguna ... year, the event is expected to bring out more than 6,000 runners, ... Day – Monday May 31. Registration is available online at www.lagunahillshalfmarathon.com ...
... , ... its place as one of the world,s leading medical hubs as it performs an ... and debilitating condition. , ... Singapore (PRWEB), May 6, 2010 -- Singapore,s oldest and largest tertiary acute hospital ...
... imaging (MRI) should be the imaging modality of choice for ... spread beyond the breast) as it is highly accurate and ... (shows no symptoms), according to a study to be presented ... Whole body MRI is a noninvasive medical test that ...
... Results from the SPIRIT IV clinical trial, which were ... scientific symposium, were published today in the New ... trial, a large-scale multi-center study of nearly 4,000 patients ... safety and efficacy in the treatment of de novo ...
... ... questions in the "By the Way, Doctor" feature. The newsletter,s May 2010 issue answers 13 ... Boston ... Letter offers answers to readers, serious, whimsical, and just plain curious questions ranging from ...
... discovered that the ovarian hormone progesterone plays a pivotal ... has important implications for breast cancer risk. ... (10.1038/nature09091; http://dx.doi.org/ ), are significant because reproductive history ... says principal investigator Rama Khokha, a molecular biologist at ...
Cached Medicine News:Health News:City of Laguna Hills Announces Memorial Day Half Marathon and 5K 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 3Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 4Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 5Health News:Whole body MRI is highly accurate in the early detection of breast cancer metastases 2Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:Harvard Health Letter Features Q&As from Harvard Doctors 2Health News:PMH cancer researchers link ovarian hormone to breast stem cells growth 2
(Date:3/30/2015)... CUPERTINO, Calif. , March 30, 2015 /PRNewswire/ ... announced that it has initiated a multi-dose Phase ... DUR-928, the lead molecule in DURECT,s Epigenomic Regulator ... entity (NCE) that may have broad applicability in ... (NAFLD) and nonalcoholic steatohepatitis (NASH).  It may also ...
(Date:3/30/2015)... Nutrastar International Inc. (OTCQB: NUIN) ("Nutrastar" or the "Company"), ... products, including commercially cultivated Cordyceps Militaris ("Cordyceps"), functional health ... results for the full year ended December 31, 2014. ... Ended December 31, 2014   , ... million in full year 2013. , ...
(Date:3/30/2015)... --  GlassesUSA , the online retailer specializing in prescription ... financing led by Viola Private Equity , a member ... business growth and accelerate their expansion as a leading player ... and B2B. GlassesUSA was founded in 2009 by ... and CTO Roy Yamner . Leveraging their vast experience ...
Breaking Medicine Technology:DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 2DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 3DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study 4Nutrastar International, Inc. Announces Full Year 2014 Results 2Nutrastar International, Inc. Announces Full Year 2014 Results 3Nutrastar International, Inc. Announces Full Year 2014 Results 4Nutrastar International, Inc. Announces Full Year 2014 Results 5Nutrastar International, Inc. Announces Full Year 2014 Results 6Nutrastar International, Inc. Announces Full Year 2014 Results 7Nutrastar International, Inc. Announces Full Year 2014 Results 8Nutrastar International, Inc. Announces Full Year 2014 Results 9GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 2GlassesUSA.com Raises $12.5 Million Growth Round Led By Viola Private Equity 3
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
For the qualitative detection of cardiac troponin I (cTnl) in human whole blood and serum specimens...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
Medicine Products: